INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Over the last two decades, Mason has served in the leadership of Lilly’s Neuroscience and Diabetes businesses to achieve significant growth and leading market positions. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.

We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases.

4 Very simple Things You are able to do To avoid wasting Time With US

This press release contains certain forward-looking statements regarding leadership changes and expectations for the future. Actual results may differ materially due to various factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will”, “anticipate” and similar expressions are intended to identify forward-looking statements.

Lilly plans to assign her function’s responsibilities amongst its executive committee members. Related to these transitions, David Hyman, MD, will become Lilly’s chief medical officer, reporting to Skovronsky, in addition to continuing to oversee oncology development; Jennifer Oleksiw will be promoted to group vice president, global chief customer officer, reporting to Ricks; and Mark Genovese, MD, most recently senior vice president of inflammation development at Gilead Sciences and Professor of Medicine/Immunology/Rheumatology emeritus at Stanford University, will join Lilly on October 16 to serve as senior vice president, Immunology Development, leading clinical development of the mid and late-stage immunology portfolio, reporting to Skovronsky. Lilly unites caring with discovery to create medicines that make life better for people around the world.

Over the last four years at the helm of Lilly Diabetes and Obesity, Mason has overseen tirzepatide’s late-stage development and unprecedented diabetes launch while establishing and preparing the company’s obesity franchise for its anticipated launch. In this capacity, Jonsson will lead Lilly’s launched products and Phase 3 portfolio of diabetes and obesity medicines, including tirzepatide. Patrik Jonsson will assume leadership of Lilly Diabetes and Obesity as executive vice president and president, effective January 1, 2024, in addition to his current responsibility as executive vice president and president of Lilly USA. A 33-year Lilly veteran with strong US and international commercial experience, Jonsson also has led Lilly Immunology and Lilly Bio-Medicines, as well as served as the general manager of Lilly Sweden, Scandinavia, Italy and Japan.